Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US. They've registered Striate+ as the new global brand for the CelGro dental bone and tissue regeneration product and the company will market the procedure in the US under this brand.
viewOrthocell Ltd
Orthocell's Paul Anderson hails FDA approval for dental bone and tissue regeneration product
Quick facts: Orthocell Ltd
Price: 0.54 AUD
ASX:OCC
Market: ASX
Market Cap: $101.93 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Orthocell makes progress with portfolio of CelGro® products within the...
Most read
Health
Cannabis company MGC Pharmaceuticals soars on food supplement product deal
6 days, 8 hours ago
Health
MGC Pharmaceuticals signs supply and distribution agreement with Swiss...
6 days, 17 hours ago
Mining
Lake Resources demonstrates clean technology path for high purity lithium as...
5 days, 19 hours ago
Mining
Bellevue Gold set to generate strong profits, robust free cashflows with...
6 days, 20 hours ago
